Read: 1011
Tianjin Medical University Cancer Institute Hospital: A Comprehensive Hub for Cancer Research and Treatment
In the face of rapidly increasing breast cancer rates in Asia, Tianjin Medical University Cancer Institute Hospital TMUCIH has taken on a pivotal role in providing cutting-edge care and medicine through its commitment to cancer research, prevention, treatment, and education. As part of this comprehensive approach, TMUCIH collaborates with China Anti-Cancer Association to develop the country's first population-based breast cancer screening guideline.
The legacy of the London Christian Church Hospital established in Tianjin in 1861 has culminated in a state-of-the-art institution dedicated to oncology research and practice. Founded as one of China's pioneering oncology departments by Xianzh Jin, the hospital is now recognized as a leading cancer prevention and treatment research center. Designated as a National Clinical Research Centre for Cancer in 2013 and its oncology program selected as part of China's elite academic development programs Ministry of Education, TMUCIH stands at the forefront of cancer diagnostics and therapies.
TMUCIH is dedicated to breaking new ground in tumor studies through integration of cross-disciplinary resources. Its Ministry of Education Key Laboratory for Breast Cancer Prevention and Treatment offers a platform for developing innovative approaches tlored to Chinese patient populations, emphasizing disease characteristics that differentiate them from Western counterparts. The laboratory's expertise includes breast cancer initiation mechanisms, molecular biology, and precision medicine strategies.
TMUCIH researchers advance understanding through multi-omics studies on gastrointestinal cancers, exploring genetic aspects of tumor genesis, metastasis, and heterogeneity to inform molecular typing, prognosis prediction, and treatment strategy design. They also investigate key regulatory pathways such as hypoxia, immunity, and angiogenesis in the progression of pancreatic, gastric, and intestinal tumors.
By leveraging cutting-edge technologies like , TMUCIH researchers are pioneering new tools for cancer diagnosis and therapy development. For instance, they have improved the analysis of ultrasound and other imaging data on thyroid tumors using deep learning algorith create an intelligent diagnostic model. The team also harnesses liquid biopsy techniques for innovative diagnosis methods.
As one of China's leading forces in anti-cancer efforts, TMUCIH is a member of the WHO's International Association of Cancer Registries IACR and Union for International Cancer Control UICC, coordinating UICC activities in China. It houses the headquarters of the China Anti-Cancer Association and works closely with international medical research institutions across more than 30 countries.
With an emphasis on international exchange, TMUCIH fosters close collaborative links to support global talent attraction and incubation programs. The institution is set to expand its capabilities by completing a new center for translational medicine and personalized cancer care treatment, providing lab space for around 100 principal investigators.
In summary, as a world-class hub for cancer prevention and treatment, TMUCIH integrates top-notch research with clinical excellence while leveraging global partnerships, positioning itself as a pivotal force in the global fight agnst cancer.
TMUCIH in Numbers:
Over 3,071 staff members including 788 medical professionals and 191 researchers
Offers services through 46 clinical departments, six research areas, 17 principal investigator teams, and five core facilities
Proudly boasts four national key clinical specialties: thoracic surgery, nursing, oncology, and pathology
Mntns a bed capacity of over 2,000 beds
Serves more than 1.25 million outpatients annually with approximately 37,053 surgeries conducted in 2019
Publishes two core journals: Chinese Journal of Clinical Oncology and Cancer Biology Medicine
Contact Information:
+86-22-23537796
www.tmucih.org
This article is reproduced from: https://www.nature.com/articles/d42473-020-00112-0
Please indicate when reprinting from: https://www.81le.com/Tumor_Cancer/Tianjin_Medical_University_Cancer_Institute_Hospital.html
Tianjin Medical University Cancer InstituteHospital Focus Asias Leading Breast Cancer Center Comprehensive Cancer Research Hub WHO International Cancer Registry Member Advanced Oncology Treatment Innovator Global Partnership in Cancer Control